molindone / Generic mfg. - LARVOL DELTA

Body Weight Gain of Antipsychotics on Children and Adolescents Within 6-8 weeks: A Network Meta-Analysis. (PubMed, Am J Ther) - "Our study indicated the effects of different antipsychotic medications on body weight gain among children. Childhood-onset schizophrenia may represent a more vulnerable group. Future studies exploring genetic and physiologic risk factors for weight gain, and potential preventive strategies, are needed."

Journal • Retrospective data • Autism Spectrum Disorder • Behavior Disorders • CNS Disorders • Genetic Disorders • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

A new species of Burmecaelidae (Orthoptera: Caelifera) sheds light on the familys possible taxonomic placement. (PubMed, Zootaxa) - "Due to similarities in morphology of the paraproctal lobes and ovipositor to Ripipterygidae Ander, 1939 (Caelifera: Tridactylidea: Tridactyloidea), as well as in forewing venation to Mongoloxyinae Gorochov, 1992 (Tridactyloidea: Tridactylidae), a taxonomic position of Burmecaelidae within Tridactylidea Brull, 1835 is suggested. The specimen ECNU-AM-0079, formerly interpreted as Burmecaelinus armis Uchida et al., 2024 by Hu & He (2024) probably does not belong to that genus, but rather to Moban Hu & He, 2024."

Journal

Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis. (PubMed, PLoS One) - "The antipsychotic medications of interest are amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, chlorpromazine, clopenthixol, clozapine, droperidol, flupenthixol, fluphenazine, haloperidol, iloperidone, levomepromazine, loxapine, lurasidone, molindone, olanzapine, paliperidone, penfluridol, perphenazine, perazine, pimozide, prochlorperazine, quetiapine, risperidone, sertindole, sulpiride, thiothixene, thioridazine, trifluoperazine, ziprasidone, zuclopenthixol and zotepine. The Cochrane Risk of Bias tool and RoB 2.0 will be used to assess the risk of bias in studies. We will evaluate the quality of the evidence contributing to network estimates for the primary outcomes using the GRADE framework, and key factors that may affect the observed effects will be analysed for consistency across studies."

Journal • Retrospective data • CNS Disorders • Sexual Disorders • PRL

Unsupervised Graph Clustering Reveals a Clinical Taxonomy of Antipsychotics (APA 2025) - "Cluster 1 contained Aripiprazole, Brexpiprazole, Cariprazine, Lurasidone, Sertindole, and Ziprasidone, and was characterized by an excellent side-effect profile but also with the lowest efficacy. Cluster 2 contained Chlorpromazine, Haloperidol, Loxapine, Molindone, Perphenazine, and Thiothixene, and showed strong efficacy in positive symptoms, but also had a high-risk for EPS, QTc prolongation and seizures. Cluster 3 contained Clozapine, Iloperidone, Olanzapine, Quetiapine, Thioridazine, and Zotepine, and showed strong overall efficacy but carried the highest risk for sedation and metabolic side effects. Cluster 4 contained Amisulpride, Asenapine, Paliperidone, Risperidone, and Sulpride, and showed excellent positive and negative symptom efficacy but carried the highest risk of hyperprolactinemia. Cluster 5 contained Flupentixol, Fluphenazine, Pimozide, and Trifluoperazine and showed the lowest efficacy with a high risk of causing EPS. Conclusion Despite traditional..."

Clinical • Anesthesia • CNS Disorders • Epilepsy • Hypotension • Psychiatry • Schizophrenia

Lurasidone versus typical antipsychotics for schizophrenia. (PubMed, Cochrane Database Syst Rev) - "We are very uncertain about whether lurasidone offers benefits to the mental state, total serious adverse events, or severe adverse events when compared to typical antipsychotics for people with schizophrenia. The evidence included in this review is of very low certainty, derived from two small trials. Study limitations (risk of bias) and imprecise results impacted our confidence in the evidence. Furthermore, data on mortality (due to suicide or natural causes) or quality of life are unavailable. Further large-scale randomized studies are needed to provide clearer insights into the benefits and harms of lurasidone compared to typical antipsychotics for treating schizophrenia."

Clinical • Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis. (PubMed, Mol Psychiatry) - "In network 2 (k = 2, n = 63), switch to molindone (k = 1, n = 9) versus switch to haloperidol worsened TD (SMD = 1.68; 95% CI = 0.61,2.76)...Despite large effect sizes for some treatments with very low quality/confidence, when considering higher quality evidence only valbenazine or deutetrabenazine are evidence-based first-line treatments for TD, and potentially vitamin E as second-line. Switching to molindone and antipsychotic washout should be avoided. More treatment options and higher-quality trials are needed."

Journal • Retrospective data • Review • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry • Schizophrenia

Irritability and Aggression in Pediatric ADHD: Current Evidence and Treatment Options (AACAP 2024) - "Among stimulant nonresponders, there is evidence to support the use of risperidone, divalproex, and citalopram augmentation. There is 1 controlled trial of molindone to reduce impulsive aggression and 1 open-label trial to support aripiprazole in DMDD... A multimodal treatment approach integrating both pharmacological and psychosocial interventions are the most efficacious strategies to improve irritability and aggression in youth with ADHD. CNS stimulant optimization leads to significant improvement in these impairing symptoms. Whenever there is a need for adjunctive treatment, atypical antipsychotics and mood stabilizers may offer additional benefit, but tolerability needs to be closely monitored to ensure a favorable risk/benefit profile.ADHD, AGG, IMD"

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis. (PubMed, Lancet Child Adolesc Health) - "Children and adolescents show varied but clinically significant physiological responses to individual antipsychotic drugs. Treatment guidelines for children and adolescents with a range of neuropsychiatric and neurodevelopmental conditions should be updated to reflect each antipsychotic drug's distinct profile for associated metabolic changes, alterations in prolactin, and haemodynamic alterations."

Clinical • Journal • Retrospective data • CNS Disorders • Psychiatry

First-Generation Antipsychotic Shortages in the United States: Analysis of Switching and Utilization Patterns (ISPOR 2024) - "As a result of a shortage or discontinuation, all individuals (100%) treated with loxapine (n=1636), molindone (n=13), thioridazine (n=1587), and trifluoperazine (n=3939) switched to another antipsychotic...Among individuals initially receiving treatment with thiothixene (n=5752), 61.6% started a different antipsychotic within one year. Individuals utilizing pimozide (9.6%) and perphenazine (16.1%) had lower switch rates. Shortages acutely changed utilization patterns of first-generation antipsychotics, resulting in multiple individuals switching treatments immediately following the official declaration of a shortage or discontinuation."

CNS Disorders • Psychiatry • Schizophrenia

Physiological Effects of Antipsychotics Across the Age Spectrum: Current Understanding and Implications for Precision Medicine (SIRS 2024) - "For cardiometabolic changes, olanzapine, quetiapine, risperidone, paliperidone, and clozapine exhibited the worst profiles, and aripiprazole, blonanserin, ziprasidone, lurasidone, and molindone the more benign profiles. For alterations in prolactin, risperidone/paliperidone performed the worst and aripiprazole the best. Incorporation of these data into the Psymatik Digital Optimizer facilitates collaborative, personalised, and evidence-based prescribing decisions."

CNS Disorders • Schizophrenia

Antipsychotic treatment in early onset of psychosis: an umbrella review of meta analytic evidence and a focus on side effects (ECNP 2023) - "Clozapine (RR=12.8) and haloperidol (RR=5.1) were associated with more dropouts because of adverse events than placebo the average weight gain experienced by EOP individuals treated with typical antipsychotics was 1.4 kg [3] EOP individuals treated with atypical antipsychotics gained an average of 4.5 kg [3] No significant weight gain compared to placebo was observed for molindone, ziprasidone, lurasidone, fluphenazine, or haloperidol (p>0.05) [4] sedation occurred in 38.3% of EOP individuals treated with typical antipsychotics, compared to 53.0% of those treated with an atypical antipsychotic (p0.05)...lurasidone (RR=5.0) and risperidone (RR=5.8) had a significantly higher risk for akathisia compared to placebo [1]] Extrapyramidal side effects were less common with asenapine than molindone (OR=0.18, 95%CI=0.03-0.97) and more common in molindone than olanzapine (OR=4.2, 95%CI=1.3-14.0) [5] To the best of our knowledge, this is the first umbrella review, including..."

Adverse events • Review • CNS Disorders • Psychiatry • Schizophrenia • Schizophreniform Disorder

Umbrella Review: Association Between Antipsychotic Drugs and Metabolic Syndrome Hallmarks in Children and Adolescents. (PubMed, J Am Acad Child Adolesc Psychiatry) - "By collating meta-analyses assessing biochemical markers of metabolic syndrome in antipsychotic-treated children, we conclude that olanzapine should not be the antipsychotic of choice in patients at risk for hypertriglyceridemia or hypercholesterolemia. Aripiprazole and lurasidone appear to be better tolerated in terms of metabolic adverse events. Insufficient meta-analytic data are available to provide a precise risk estimate of metabolic syndrome, and, overall, the quality of evidence is low."

Journal • Review • CNS Disorders • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pediatrics

An Update on Irritability in Youth with Attention-Deficit/Hyperactivity Disorder (ASCP 2023) - "When aggression persists, there was evidence that risperidone, and to a lesser degree, divalproex augmentation led to further improvements. There was one controlled trial to support SSRIs for severe irritability and for molindone to reduce impulsive aggression, one open label trial to support aripiprazole, and none for nonstimulants or other medications where irritability was specifically reported as an outcome Children with ADHD often exhibit persistent irritability and impulsive aggression that are associated with significant impairment... Children with ADHD often exhibit persistent irritability and impulsive aggression that are associated with significant impairment. A multimodal treatment approach integrating both pharmacological and psychosocial interventions are the most efficacious for improving these issues in youth with ADHD. Adjunctive treatment with atypical antipsychotic and mood stabilizer targeting these symptoms may offer additional benefit if these..."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Depression • Psychiatry

Comparative Effects of 30 Antipsychotics on Risk of Catatonia: An Analysis of the WHO Pharmacovigilance Database. (PubMed, J Clin Psychiatry) - "The highest RORs were found for molindone (6.0; 95% CI, 3.1-10.4) and haloperidol (3.8; 95% CI, 3.5-4.0). This increased risk is consistent with the pharmacodynamic hypothesis of antipsychotic-induced catatonia. Our results warrant replication in population-based studies."

Adverse events • Journal • Observational data • CNS Disorders • Mental Retardation • Psychiatry

Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs. (PubMed, Pharmacopsychiatry) - "Evidence supported the efficacy of aripiprazole, clozapine, haloperidol, lurasidone, molindone, olanzapine, quetiapine, risperidone and paliperidone in EOS, all of which obtained approval for EOS either in Europe and/or in North-America. Future long-term trials looking at cognition, functioning, quality of life, suicidal behaviour, mortality, services utilisation and cost-effectiveness are warranted. Closer multi-agency collaboration may bridge the gap between evidence, guidelines and approved drugs."

Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

Updates in Pharmacologic Strategies for Emotional Dysregulation in Attention Deficit Hyperactivity Disorder. (PubMed, Child Adolesc Psychiatr Clin N Am) - "Randomized controlled trials support that addition of risperidone further reduces aggression when these treatments are not sufficient. There is evidence for the efficacy of divalproex, molindone and selective serotonin reuptake inhibitor improve these outcomes when used as adjunct to CNS stimulants."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Identification of lncRNA Biomarkers and LINC01198 Promotes Progression of Chronic Rhinosinusitis with Nasal Polyps through Sponge miR-6776-5p. (PubMed, Biomed Res Int) - "In addition, we predicted 5 small molecule drugs to treat CRSwNP by analyzing 19 central immune genes, namely, danazol, ikarugamycin, semustine, cefamandole, and molindone. The results of this study showed that LINC01198 promoted the progression of CRSwNPs through spongy miR-6776-5p. Our studies provide a new way for further analyses of the pathogenesis of CRSwNP."

Biomarker • Journal • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Dopamine Receptor Antagonist-Induced Elevation of the Compulsion Zone Results in Differential Effects on Cocaine Self-Administration and Lever-Pressing Behavior. (PubMed, FASEB J) - "The dopamine receptor antagonists, SCH23390 (10-30 nmol/kg), eticlopride (10-30 nmol/kg), or molindone (750-3000 nmol/kg) were administered i.v. either while cocaine was accessible during the maintenance phase or following termination of access denoting the start of the unloading phase. The faster elimination of cocaine at these elevated levels results in cocaine levels transiting the compulsion zone more rapidly. The differential effect of dopamine receptor antagonists on lever-pressing behavior may provide insights to the appropriate use of antagonists as medications for cocaine use disorder."

Journal

Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis. (PubMed, J Clin Psychopharmacol) - "Some antipsychotics were effective and tolerated short term, but longer-term evidence was very limited. The overall paucity of trials and of adequate controls indicates that more well-designed randomized controlled trials are required for adequate assessment of antipsychotic drug treatment for juveniles."

Journal • Retrospective data • Review • CNS Disorders • Psychiatry

Pharmacotherapy Of Aggression: When Might It Be Indicated? (AACAP 2021) - "Methylphenidate (MTH) showed efficacy in half of patients with ADHD and aggression...The addition of clonidine to MTH may be effective based on a randomized controlled trial. Several clinical trials reported that typical antipsychotics, including molindone, thioridazine, haloperidol, and chlorpromazine, may reduce aggressive behaviors in youth with conduct disorder. Several second-generation antipsychotics (SGAs), such as quetiapine, olanzapine, and aripiprazole, may be effective in the treatment of aggression in youth with DBDs. Risperidone, which is well-studied in aggressive youth, showed efficacy in reducing aggression in both short- and long-term maintenance treatment...Current evidence supports the use of stimulants and some alpha-2 agonists in aggressive youth with ADHD and the use of antipsychotics in children with conduct problems. Future research should focus on developing an evidence-based nosology of aggression in children so that psychopharmacological..."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort. (PubMed, Am J Clin Nutr) - "Our findings suggested that folate intakes in GWs 9 to 12 and midpregnancy were associated with a lower risk of CP, while no association was observed for periconceptional supplementation."

Journal • Cerebral Palsy • CNS Disorders • Developmental Disorders • Psychiatry

Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs. (PubMed, Clin Rheumatol) - "• We explored the molecular mechanism and immunological landscape of dermatomyositis. • GO analysis showed that DEGs were enriched in immune-related pathways. • We predicted small-molecular drugs with potential therapeutic significance based on bioanalytical techniques. • We identified six immune cells with differential infiltration in patients with DM and controls."

Biomarker • Journal • Dermatomyositis • Immunology • Inflammation • Myositis

Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. (PubMed, CNS Drugs) - "According to two case reports, carbamazepine is a clinically relevant inducer of methylphenidate (MPH). A case series study suggested that MPH may be associated with important elevations in imipramine concentrations. Due to the absence of or limitations in the data, no comments for clinicians can be provided on the pharmacokinetic DDIs for clonidine, centanafadine, mazindol, molindone, AR-08, P. tenuifolia extract and the French maritime pine bark extracts...A summary table for clinicians provides our current recommendations on pharmacokinetic DDIs of ADHD agents based on our literature review and the package inserts; whenever it was possible, we provide information on serum concentrations and dose correction factors. There will be a need to periodically update these recommendations and these correction factors as new knowledge becomes available."

Clinical • Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. (PubMed, J Child Adolesc Psychopharmacol) - P4 | "TEOSS randomized 119 predominantly outpatient youth ages 8-19 years with schizophrenia or schizoaffective disorder to 8 weeks of treatment with molindone, risperidone, or olanzapine. Furthermore, while lack of early improvement predicted clinical nonresponse, whether or not to continue antipsychotic treatment after 3 or more weeks without symptom improvement should be based on clinical judgment after weighing potential risks, benefits, and alternatives. ClinicalTrials.gov Identifier: NCT00053703."

Clinical • Journal • CNS Disorders • Pediatrics • Psychiatry • Schizophrenia

[VIRTUAL] Toward Development of an Abbreviated PANSS for Pediatric Trials: Secondary Analyses of TEOSS and Other Psychopharmacologic Data Sets (ASCP 2020) - " As part of an NIMH multisite study on schizophrenia (TEOSS study, completed and described previously; Sikich, et al, 2008), 116 8-10 year olds with schizophrenia/schizoaffective disorder were administered the PANSS at baseline and weekly throughout an 8 week randomized double blind study of molindone, risperidone, or olanzapine. The work should inform the field and has the potential to result in an empirically derived shortened PANSS specific to children and adolescents. Learning Objectives: 1) Attendees will become familiar with challenges associated with pediatric psychosis assessment tools for psychopharmacology trials 2) Attendees will become familiar with item response theory and other statistical analyses applied uniquely to an NIMH pediatric psychosis dataset with the goal of selecting most useful PANSS items for pediatric trials."

Clinical • CNS Disorders • Schizophrenia